Caribou Biosciences (CRBU) Stock
Clinical stage biotech developing gene editing therapies. Here's the price, business snapshot, and what's worth knowing about Caribou Biosciences in June 2026.
Caribou Biosciences (CRBU) is a clinical-stage biotechnology company developing CRISPR-based gene-editing platforms and therapeutic candidates. The business focuses on creating engineered cell therapies and in vivo programmes that aim to correct or modify genes to treat disease. With a market capitalisation of roughly $264.5 million, Caribou sits in the small-cap, high-volatility segment of the biotech market: scientific milestones, trial results and partner deals can move the shares sharply. Key considerations for investors include clinical and regulatory risk, the long timelines typical of drug development, capital requirements, and the importance of collaborations or licences to scale commercialisation. Intellectual property and the company’s technical platform are central value drivers, but outcomes are binary and uncertain. This summary is for educational purposes only and not personalised financial advice; investors should assess suitability, diversification and time horizon and consult a qualified adviser before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Caribou Biosciences' stock, indicating strong potential for price increase.
Financial Health
Caribou Biosciences has modest revenue and cash flow, indicating steady but unspectacular financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring CRBU
Biotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: 11 July 2025
Explore BasketAI-Driven Drug Discovery
These groundbreaking companies are redefining pharmaceutical research with artificial intelligence. Each has been carefully selected by our analysts for their potential to develop life-saving drugs faster and more efficiently than traditional methods allow.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Matter
Progress in trials can re-rate the stock quickly, though trial outcomes are uncertain and may not lead to approval.
Platform Potential
Caribou’s CRISPR platform is a core value driver; strong IP and partnerships can accelerate development but do not remove scientific risk.
Partnerships & Scale
Collaborations with larger pharmas can provide validation and funding, yet commercialisation remains long-term and capital-intensive.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
